Abstract
The caudal-related homeobox transcription factor CDX2 regulates the differentiation of intestinal epithelial cells. Recent studies have suggested that CDX-2 immunoreactivity is strictly confined to benign and malignant intestinal epithelium. In the present study, we evaluated the prevalence of CDX2 immunoreactivity in a series of benign, borderline and malignant primary ovarian mucinous neoplasms. We tested 62 mucinous tumours of the ovary, including 28 benign cystadenomas, 18 borderline tumours, 16 adenocarcinomas, 35 serous and endometrioid ovarian lesions and 10 ovarian metastases of colonic adenocarcinoma. Overall, the CDX2 prevalence in primary mucinous tumours was 79%, including 20 of 28 (71.5%) cystadenomas, 14 of 18 (77.7%) borderline tumours and 15 of 16 (93.5%) adenocarcinomas. Immunoreactivity usually correlated with intestinal differentiation of tumour cells, although wide heterogeneity in the distribution of immunolabelled cells was noted. No immunoreactivity was observed in serous lesions; whereas, 1 of 13 (7.7%) endometrioid adenocarcinomas and all of the 10 metastatic colonic adenocarcinomas were immunostained. These results indicate that CDX2 is detectable in the majority of benign, borderline and malignant ovarian mucinous tumours and, therefore, makes this marker unsuitable when distinguishing primary from metastatic ovarian mucinous adenocarcinomas. However, CDX2 immunoreactivity could be useful in the distinction between endocervical and intestinal-type mucinous tumours of the ovary, which may have clinical relevance.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bai YQ, Yamamoto H, Akiyama Y, Tanaka H, Takizawa T, Koike M, Kenji Yagi O, Saitoh K, Takeshita K, Iwai T, Yuasa Y (2002) Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach. Cancer Lett 176:47–55
Barbareschi M, Murer B, Colby TV, Chilosi M, Macri E, Loda M, Doglioni C (2003) CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. Am J Surg Pathol 27:141–149
Berezowski K, Stastny JF, Kornstein MJ (1996) Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol 9:426–429
Burry RW (2000) Specificity controls for immunocytochemical methods. J Histochem Cytochem 48:163–166
Eda A, Osawa H, Yanaka I, Satoh K, Mutoh H, Kihira K, Sugano K (2002) Expression of homeobox gene CDX2 precedes that of CDX1 during the progression of intestinal metaplasia. J Gastroenterol 37:94–100
Groisman GM, Meir A (2003) The intestinal marker CDX2 is useful in differentiating primary ovarian carcinoma from metastatic colonic carcinoma. Mod Pathol 16:190A
Lee KR, Scully RE (2000) Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with pseudomyxoma peritonei. Am J Surg Pathol 24:1447–1464
Lee KR, Young RH (2003) The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol 27:281–292
Lorentz O, Duluc I, Arcangelis AD, Simon-Assmann P, Kedinger M, Freund JN (1997) Key role of the Cdx2 homeobox gene in extracellular matrix-mediated intestinal cell differentiation. J Cell Biol 139:1553–1565
McCluggage WG (2002) Recent advances in immunohistochemistry in gynecological pathology. Histopathology 40:309–326
Mizoshita T, Inada K, Tsukamoto T, Kodera Y, Yamamura Y, Hirai T, Kato T, Joh T, Itoh M, Tatematsu M (2001) Expression of Cdx1 and Cdx2 mRNAs and relevance of this expression to differentiation in human gastrointestinal mucosa—with special emphasis on participation in intestinal metaplasia of the human stomach. Gastric Cancer 4:185–191
Qualtrough D, Hinoi T, Fearon E, Paraskeva C (2002) Expression of CDX2 in normal and neoplastic human colon tissue and during differentiation of an in vitro model system. Gut 5:184–190
Scully RE, Young RH, Clement PB (1998) Mucinous tumors and pseudomyxoma peritonei. In: J Rosai (ed) Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Armed Forces Institute of Pathology, Washington, DC, pp 81–106
Seno H, Oshima M, Taniguchi MA, Usami K, Ishikawa TO, Chiba T, Taketo MM (2002) CDX2 expression in the stomach with intestinal metaplasia and intestinal-type cancer: prognostic implications. Int J Oncol 21:769–774
Silberg DG, Sullivan J, Kang E, Swain GP, Moffett J, Sund NJ, Sackett SD, Kaestner KH (2002) Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 122:689–696
Siriaunkgul S, Robbins KM, McGowan L, Silverberg SG (1995) Ovarian mucinous tumors of low malignant potential: a clinicopathologic study of 54 tumors of intestinal and mullerian type. Int J Gynecol Pathol 14:198–208
Suh E, Traber PG (1996) An intestine-specific homeobox gene regulates proliferation and differentiation. Mol Cell Biol 16:619–625
Wang N-P, Zee S, Zarbo RJ, Bacchi CE, Gown AM (1995) Coordinate expression of cytokeratins 7 and 20 define unique subsets of carcinoma. Appl Immunohistochem 3:99–107
Werling RW, Yaziji H, Bacchi CE, Gown AM (2003) CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 27:303–310
Acknowledgement
The authors thank Mr. Steven Lawson for the English revision of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fraggetta, F., Pelosi, G., Cafici, A. et al. CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours. Virchows Arch 443, 782–786 (2003). https://doi.org/10.1007/s00428-003-0910-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-003-0910-3